In the Era of Bortezomib-based Induction, Intensification of Melphalan-based Conditioning with Bortezomib Does Not Improve Survival Outcomes in Newly Diagnosed Multiple Myeloma: a Study from the Chronic Malignancies Working Party of the EBMT